These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 7533183)
1. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. Yang G; Hellström KE; Hellström I; Chen L J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183 [TBL] [Abstract][Full Text] [Related]
2. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski TF; Fallarino F; Uyttenhove C; Boon T J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031 [TBL] [Abstract][Full Text] [Related]
4. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. Gajewski TF J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795 [TBL] [Abstract][Full Text] [Related]
5. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025 [TBL] [Abstract][Full Text] [Related]
6. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958 [TBL] [Abstract][Full Text] [Related]
7. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681 [TBL] [Abstract][Full Text] [Related]
8. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214 [TBL] [Abstract][Full Text] [Related]
10. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell RA; Kerkvliet NI J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803 [TBL] [Abstract][Full Text] [Related]
11. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules. Mauri D; Wyss-Coray T; Gallati H; Pichler WJ J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409 [TBL] [Abstract][Full Text] [Related]
13. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal. Zhou T; Weaver C; Linsley PS; Mountz JD Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125 [TBL] [Abstract][Full Text] [Related]
14. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. Tao X; Constant S; Jorritsma P; Bottomly K J Immunol; 1997 Dec; 159(12):5956-63. PubMed ID: 9550393 [TBL] [Abstract][Full Text] [Related]
15. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease. Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636 [TBL] [Abstract][Full Text] [Related]
16. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249 [TBL] [Abstract][Full Text] [Related]
17. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919 [TBL] [Abstract][Full Text] [Related]
19. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988 [TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. Chen C; Gault A; Shen L; Nabavi N J Immunol; 1994 May; 152(10):4929-36. PubMed ID: 7513726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]